Krokodil is the street name for a homemade injectable opioid whose active ingredient is desomorphine, a semi-synthetic opioid ~10× more potent than morphine. [1] Synthesized from codeine tablets using caustic soda, gasoline, hydrochloric acid, iodine, and red phosphorus, the resulting unpurified solution contains highly toxic contaminants (iodine, phosphorus, heavy metals, organic solvents) responsible for the devastating tissue destruction that distinguishes krokodil from other injected opioids. [2-3] The name derives from the characteristic green, scaly, crocodile-like skin at injection sites. [4]
1. History
- Duration, frequency, and route of krokodil use (IV vs. skin-popping)
- Injection sites used (arms, groin, neck, legs) and progression of site changes
- Onset and progression of skin lesions: color change → ulceration → necrosis
- Associated symptoms: pain at injection site, fevers, chills, weight loss, bone pain, jaw pain
- Prior heroin or other opioid use; reason for switching to krokodil (cost, availability)
- Needle-sharing practices and equipment used
- Last dose and timing (critical for withdrawal assessment)
- Important negatives: chest pain, dyspnea, neurologic deficits, hematuria
2. Alarm Features
- Rapidly progressive gangrene or necrosis extending beyond injection site — suggests necrotizing fasciitis [5]
- Pain out of proportion to exam (may be misperceived as drug-seeking) — high suspicion for necrotizing soft tissue infection (NSTI) [6]
- Crepitus, hemorrhagic bullae, violaceous skin changes
- Sepsis signs: fever, tachycardia, hypotension, altered mental status
- Exposed bone or tendon at wound site
- Jaw pain with exposed bone — osteonecrosis of the jaw (phosphorus-related) [7]
- Signs of endocarditis: new murmur, splinter hemorrhages, Janeway lesions [8]
- Respiratory distress (septic emboli, pneumonia, wound botulism)
- Bulbar symptoms (diplopia, dysphagia, dysarthria) — consider wound botulism [9]
3. Medications
Relevant contributors
Common treatments
- Opioid withdrawal management: buprenorphine or methadone are first-line for opioid use disorder (OUD) treatment; clonidine or lofexidine for symptomatic withdrawal relief [10-11]
- Symptomatic withdrawal adjuncts: loperamide (diarrhea), ondansetron (nausea), NSAIDs (myalgias), benzodiazepines (anxiety/insomnia) [12]
- Wound infections: broad-spectrum antibiotics covering gram-positives (including MRSA), anaerobes, and oral flora; empiric clindamycin if GAS suspected [13-14]
- Tetanus prophylaxis — verify immunization status [9]
Contraindications/cautions
- Avoid naltrexone initiation until opioid-free for 7–10 days [15]
- Buprenorphine initiation may precipitate withdrawal if started too early; use COWS scoring [16]
- Desomorphine has a short half-life (~2–3 hours), leading to very frequent dosing and rapid withdrawal onset [1]
4. Diet
- Severe malnutrition is common; caloric and protein supplementation for wound healing
- Correct micronutrient deficiencies: vitamin C, zinc, iron, B vitamins
- Hydration is critical, especially during withdrawal (vomiting, diarrhea) and sepsis
- No specific dietary triggers; focus on nutritional rehabilitation
5. Review of Systems
- Skin: ulcers, discoloration (green/black), scaly lesions, abscess drainage, track marks
- MSK: bone pain (osteomyelitis, osteonecrosis), jaw pain, myalgias
- Oral: tooth decay, gingival disease, jaw swelling or exposed bone [7]
- Cardiovascular: chest pain, dyspnea, peripheral edema (endocarditis, DVT)
- Neurologic: weakness, bulbar symptoms (wound botulism), paresthesias
- GI: nausea, vomiting, diarrhea (withdrawal), abdominal pain
- Constitutional: fevers, night sweats, weight loss
- Psychiatric: depression, suicidality, anxiety
6. Collateral History and Family History
- Collateral from friends, family, or other users regarding substance use patterns, injection practices, and needle sharing
- Social context: housing instability, incarceration history, access to harm reduction services
- Family history of substance use disorders
- Prior treatment attempts for OUD
- Sexual history (risk for HIV, HBV, HCV transmission) [17]
7. Risk Factors
- Heroin unavailability or cost — krokodil emerged as a cheap substitute (~$6–8/dose vs. heroin) [18-19]
- Geographic: originally Russia/Ukraine (estimated 100,000+ users in Russia by 2011), now spreading to Europe and North America [18]
- Needle sharing and communal drug preparation [20]
- Skin-popping (subcutaneous injection) — 5× increased SSTI risk vs. IV injection [6]
- Homelessness, poverty, lack of access to opioid agonist therapy
- Comorbid psychiatric illness
- HIV-positive krokodil users may inject 85% more frequently than those unaware of their status [20]
8. Differential Diagnosis
- Necrotizing fasciitis (clostridial or polymicrobial) — crepitus, rapid spread, systemic toxicity [5]
- Xylazine-related skin ulcers ("tranq wounds") — similar necrotic ulcers, increasingly common in US [6]
- Levamisole-induced vasculopathy (cocaine adulterant) — retiform purpura, neutropenia [6]
- Calciphylaxis — painful necrotic skin lesions in ESRD patients
- Pyoderma gangrenosum — painful ulcers with violaceous undermined borders
- Wound botulism — descending paralysis, bulbar symptoms in IDU [9]
- Phosphorus poisoning (systemic) — hepatotoxicity, "phossy jaw" osteonecrosis [4][7]
- Arterial insufficiency/peripheral vascular disease — chronic ulcers, absent pulses
9. Past Medical History
- Prior opioid use disorder and treatment history (methadone, buprenorphine, naltrexone)
- Previous skin/soft tissue infections, abscesses, surgical debridements, amputations
- History of DVT/PE, thrombophlebitis
- Bloodborne infections: HIV, HCV, HBV status [17][20]
- Tetanus vaccination status
- Dental history (osteonecrosis of jaw) [7]
- Psychiatric history and prior overdoses
10. Physical Exam
Vital signs: Fever, tachycardia, hypotension (sepsis); hypertension, tachycardia (withdrawal)
Focused exam
- Skin: Green/black discoloration, scaly desquamation at injection sites, ulcers with necrotic base, exposed subcutaneous tissue/bone, track marks, abscesses, crepitus, surrounding erythema [1][4][6]
- Vascular: Thrombophlebitis, absent peripheral pulses, venous sclerosis
- Oral/maxillofacial: Exposed bone (osteonecrosis of jaw), dental caries, gingival inflammation [7]
- Cardiac: New murmurs (endocarditis), JVD
- Neurologic: Cranial nerve palsies, descending weakness (botulism), pupil size (miosis vs. mydriasis in withdrawal)
- MSK: Bony tenderness (osteomyelitis), joint effusions (septic arthritis)
- Lymph nodes: Regional lymphadenopathy
11. Lab Studies
- CBC with differential: Leukocytosis (infection/sepsis), anemia (chronic disease, blood loss)
- CMP: Renal function (nephrotoxicity from heavy metals, rhabdomyolysis), hepatic function (hepatotoxicity from phosphorus/solvents, viral hepatitis), electrolytes [21]
- CRP/ESR: Inflammatory markers for infection severity
- Lactate: Sepsis evaluation
- Blood cultures (×2 sets minimum): Endocarditis, bacteremia
- Wound cultures: Aerobic and anaerobic (including clostridial species) [22]
- CK: Rhabdomyolysis screening
- Coagulation studies: DIC screening in severe sepsis
- Urine drug screen: Standard opiate immunoassays have variable cross-reactivity with desomorphine (2.5–77%); morphine-directed assays perform better [23]
- Infectious disease screening: HIV, HCV antibody/RNA, HBV panel, RPR/VDRL [6][17]
- Thyroid function: Iodine excess from contaminants may cause thyroid dysfunction
12. Imaging
- X-ray of affected extremity: Gas in soft tissues (NSTI, gas gangrene), osteomyelitis, foreign bodies
- CT with contrast: Extent of soft tissue infection, abscess localization, gas tracking; CT of jaw for osteonecrosis [7]
- MRI: Gold standard for osteomyelitis evaluation; delineation of deep tissue involvement
- Echocardiography (TTE → TEE): If endocarditis suspected [8]
- Panoramic radiograph (OPG): Jaw osteonecrosis evaluation [7]
- Imaging is unnecessary for simple superficial abscesses amenable to bedside I&D
13. Special Tests
- LRINEC score (Laboratory Risk Indicator for Necrotizing Fasciitis): WBC, hemoglobin, sodium, glucose, creatinine, CRP — score ≥6 has PPV 92% for NSTI in general populations, though performance is reduced in PWID [5][24]
- COWS (Clinical Opiate Withdrawal Scale): Standardized withdrawal severity assessment [25]
- Point-of-care ultrasound: Abscess identification, vascular access assessment, cardiac evaluation
- Wound botulism antitoxin testing if bulbar symptoms present [9]
- GC-MS/LC-MS confirmation: Definitive identification of desomorphine in urine/blood if needed [23][26]
- Bone biopsy: Culture and histopathology for osteomyelitis/osteonecrosis confirmation
14. ECG
- Obtain ECG in all patients with systemic illness, sepsis, or chest pain
- QTc prolongation: May occur with methadone use during OUD treatment; baseline ECG recommended before methadone initiation
- Endocarditis-related conduction abnormalities (heart block from perivalvular abscess)
- Electrolyte derangements (hypokalemia, hypomagnesemia) may cause arrhythmias
- Evaluate for ischemic changes if concern for septic coronary emboli
15. Assessment
Krokodil produces a dual-injury pattern: opioid-related effects (dependence, overdose, withdrawal) and contaminant-driven tissue destruction that is uniquely severe among injected drugs. [1-2][27]
Localized complications (most common)
- Injection-site skin necrosis, ulceration, and gangrene — the hallmark "crocodile skin" [1][4]
- Thrombophlebitis and venous sclerosis [28]
- Deep soft tissue infection, abscess, necrotizing fasciitis [2]
- Osteomyelitis of extremities [4]
Regional complications
- Osteonecrosis of the jaw[7]
Systemic complications
- Sepsis and multiorgan failure [4]
- Bloodborne infections: HIV (45% prevalence among krokodil injectors in Ukraine), HCV, HBV [20]
- Endocarditis, septic emboli [8]
- Hepatotoxicity and nephrotoxicity from heavy metals and phosphorus [4][21]
- Pneumonia, lung abscess
- Limb amputation — frequently required [1-2]
- Average life expectancy after starting krokodil use: ~1–3 years [27]
16. Treatment Plan
Initial stabilization (ED)
- ABCs; IV access, fluid resuscitation if septic
- Naloxone for acute opioid overdose
- Broad-spectrum antibiotics if infection suspected (vancomycin + piperacillin-tazobactam or meropenem for polymicrobial/anaerobic coverage) [13-14]
- Tetanus prophylaxis
- Pain management (multimodal; avoid pure opioid agonists if possible, though may be necessary)
Wound management
- Urgent surgical consultation for debridement if NSTI, gas gangrene, or extensive necrosis [5]
- Serial wound assessments q4–6h if diagnosis uncertain [5]
- I&D of abscesses; wound cultures (aerobic + anaerobic)
- Wound care with dressing changes; negative-pressure wound therapy for large defects
Opioid use disorder treatment
- Initiate buprenorphine (preferred) or methadone during hospitalization — this is a critical intervention window [10][15]
- Desomorphine's short half-life (~2–3 hours) means withdrawal onset is rapid; COWS-guided buprenorphine initiation can often proceed within hours of last use [25]
- Symptomatic adjuncts: clonidine, loperamide, ondansetron, NSAIDs [12]
Infectious disease management
- Screen for HIV, HCV, HBV, syphilis [6][17]
- Initiate ART if HIV-positive; direct-acting antivirals if HCV-positive [29]
- Vaccinate: HAV, HBV, tetanus, influenza, pneumococcal as indicated
Maxillofacial
17. Disposition
Admit if
- Sepsis, hemodynamic instability, or systemic toxicity
- Suspected NSTI requiring surgical exploration
- Extensive gangrene or necrosis requiring serial debridements
- Endocarditis or other deep-seated infection
- Severe opioid withdrawal refractory to outpatient management
- Multiorgan dysfunction (AKI, hepatic failure)
- Wound botulism (ICU admission for airway monitoring)
Observation
Discharge considerations
- Simple abscess post-I&D with reliable follow-up
- Stable wound with outpatient wound care arranged
- OUD treatment plan in place (buprenorphine prescription or methadone clinic referral)
Specialist consultation triggers
- Surgery (general, vascular, or orthopedic): NSTI, gangrene, amputation evaluation
- OMFS: Jaw osteonecrosis [7]
- Infectious disease: Endocarditis, osteomyelitis, complex bacteremia
- Addiction medicine: OUD treatment initiation and long-term planning
- Psychiatry: Suicidality, severe comorbid psychiatric illness
18. Follow Up / Return Precautions
Follow-up timing
- Wound recheck within 48–72 hours post-discharge
- OUD treatment follow-up within 1 week of buprenorphine/methadone initiation
- Infectious disease screening results review within 1–2 weeks
Return immediately for
- Worsening redness, swelling, or pain at wound sites
- Fever, chills, or feeling systemically unwell
- New skin discoloration or spreading necrosis
- Jaw pain, swelling, or exposed bone
- Chest pain, shortness of breath, or new neurologic symptoms
- Inability to tolerate oral intake
Patient counseling
- Krokodil carries an exceptionally high mortality rate; average survival is estimated at 1–3 years of use [27]
- Harm reduction: sterile needle programs, naloxone distribution, safe injection education
- OUD treatment with buprenorphine or methadone significantly reduces overdose death risk [15]
- Connect with addiction services, social work, and housing resources
References
1. DARK Classics in Chemical Neuroscience: Krokodil. — Alves EA. ACS Chemical Neuroscience. 2020.
2. The Harmful Chemistry Behind Krokodil (Desomorphine) Synthesis and Mechanisms of Toxicity. — Alves EA, Grund JP, Afonso CM, et al. Forensic Science International. 2015.
3. The Harmful Chemistry Behind "Krokodil": Street-Like Synthesis and Product Analysis. — Alves EA, Soares JX, Afonso CM, et al. Forensic Science International. 2015.
4. "Krokodil"-a Menace Slowly Spreading Across the Atlantic. — Oliver T, Gheevarghese SJ, Gandhi U, Bhat ZY, Pillai U. American Journal of Therapeutics. 2014.
5. Necrotizing Soft Tissue Infections: A Review. — McDermott J, Kao LS, Keeley JA, et al. JAMA Surgery. 2024.
6. Medical Complications of Injection Drug Use — Part I. — Rich KM, Solomon DA. NEJM Evidence. 2023.
7. Effects of Krokodil (Desomorphine) Use on Oral Health - A Systematic Review. — van Kempen EEJ, Brand HS. British Dental Journal. 2019.
8. Infectious Complications of Injection Drug Use. — Marks LR, Nolan NS, Liang SY, Durkin MJ, Weimer MB. The Medical Clinics of North America. 2022.
9. View From the Front Lines: An Emergency Medicine Perspective on Clostridial Infections in Injection Drug Users. — Gonzales y Tucker RD, Frazee B. Anaerobe. 2014.
10. Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose. — Harris MTH, Weinstein ZM, Walley AY. The Journal of the American Medical Association. 2026.
11. Clinical Policy: Critical Issues Related to Opioids in Adult Patients Presenting to the Emergency Department. — Hatten BW, Cantrill SV, Dubin JS, et al. Annals of Emergency Medicine. 2020.
12. Treatment of Opioid-Use Disorders. — Schuckit MA. The New England Journal of Medicine. 2016.
13. Necrotising Soft-Tissue Infections. — Hua C, Urbina T, Bosc R, et al. The Lancet. Infectious Diseases. 2023.
14. Community-Acquired Skin and Soft-Tissue Infections in People Who Inject Drugs. — Allaw F, Zakhour J, Kanj SS. Current Opinion in Infectious Diseases. 2023.
15. Medications to Treat Opioid Use Disorder. — Walter K. The Journal of the American Medical Association. 2026.
16. ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-Potency Synthetic Opioids. — Weimer MB, Herring AA, Kawasaki SS, et al. Journal of Addiction Medicine. 2023.
17. Viral Infections Associated With Injection Drug Use. — Assoumou SA, Alexander RN, Miller SE. The Journal of the American Medical Association. 2025.
18. Breaking Worse: The Emergence of Krokodil and Excessive Injuries Among People Who Inject Drugs in Eurasia. — Grund JP, Latypov A, Harris M. The International Journal on Drug Policy. 2013.
19. A "Krokodil" Emerges From the Murky Waters of Addiction. Abuse Trends of an Old Drug. — Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S. Life Sciences. 2014.
20. Krokodile Injectors in Ukraine: Fueling the HIV Epidemic?. — Booth RE, Davis JM, Brewster JT, Lisovska O, Dvoryak S. AIDS and Behavior. 2016.
21. Renal Manifestations of Recreational Drugs: A Narrative Review of the Literature. — Kannan L. Medicine. 2022.
22. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
23. Desomorphine Screening Using Commercial Enzyme-Linked Immunosorbent Assays. — Winborn J, Kerrigan S. Journal of Analytical Toxicology. 2017.
24. Predicting Necrotising Soft Tissue Infections in People Who Inject Drugs: Poor Performance of the Laboratory Risk Indicator for Necrotising Fasciitis Score and Development of a Novel Clinical Predictive Nomogram in a Retrospective Cohort With Internal Validation. — MacLeod CS, O'Neill HL, Shaalan R, et al. International Journal of Surgery. 2023.
25. Management of Opioid Use Disorder in the USA: Present Status and Future Directions. — Blanco C, Volkow ND. Lancet. 2019.
26. Metabolic Fate of Desomorphine Elucidated Using Rat Urine, Pooled Human Liver Preparations, and Human Hepatocyte Cultures as Well as Its Detectability Using Standard Urine Screening Approaches. — Richter LH, Kaminski YR, Noor F, Meyer MR, Maurer HH. Analytical and Bioanalytical Chemistry. 2016.
27. Desomorphine (Krokodil): An Overview of Its Chemistry, Pharmacology, Metabolism, Toxicology and Analysis. — Florez DHÂ, Dos Santos Moreira AM, da Silva PR, et al. Drug and Alcohol Dependence. 2017.
28. Desomorphine Goes "Crocodile". — Gahr M, Freudenmann RW, Hiemke C, et al. Journal of Addictive Diseases. 2012.
29. Viral Infections Related to Injection Drug Use. — Borelli C. The Journal of the American Medical Association. 2025.